

April 30, 2024

Chairman Tom Cole
2207 Rayburn House Office Building
Washington, DC 20515

Senator Patty Murray
154 Russell Senate Office Building
Washington, DC 20510

Ranking Member Rosa DeLauro
2413 Rayburn House Office Building
Washington, DC 20515

Senator Susan Collins
413 Dirksen Senate Office Building
Washington, DC 20510

Chairman Mario Diaz Balart
374 Cannon House Office Building
Washington, DC 20515

Senator Chris Coons
218 Russell Senate Office Building
Washington, DC 20510

Ranking Member Barbara Lee
2470 Rayburn House Office Building
Washington, DC 20515

Senator Lindsey Graham
290 Russell Senate Office Building
Washington, DC 20510

Dear Chairman Cole, Ranking Member DeLauro, Chairman Diaz Balart, Ranking Member Lee, Senator Murray, Senator Collins, Senator Coons, and Senator Graham:

As representatives of leading companies and private sector organizations, we extend our gratitude to you for the \$1.65 billion contribution to the Global Fund to Fight AIDS, Tuberculosis, and Malaria in FY2024 and write to express our strong support for the Biden Administration's request of \$1.2 billion in FY2025, meeting the U.S. pledge to fund 33% of the three-year replenishment. The lifesaving work of the Global Fund—fueled by the robust support of the United States and of others it rallies—has improved the health, stability, and economic viability of low- and middle-income countries, and can yield significant benefits for American businesses, employees and citizens.

Investing at least \$1.2 billion will continue momentum in ending the HIV/AIDS, TB and malaria epidemics, preventing future health emergencies, attaining measurable economic benefits and promoting of the United States' own brand in a competitive world.

This investment would catalyze that of other countries and encourage stronger pledges for the next replenishment. The U.S. commitment at the Global Fund replenishment conference it hosted in 2022 and far-sighted appropriations propelled record donor pledges: Canada, Japan, Germany, France, and the European Commission increased their pledges proportionally as much as the U.S. A robust U.S. contribution for FY 25 would signal unflagging U.S. leadership in global health, spurring other donors.

Leading private sector companies support the Global Fund because it saves lives and builds stronger health systems, protecting personnel and communities where we operate and promoting security, good diplomatic relations, transparency and inclusive governance. The Global Fund is focused on the bottom line: saving lives and ending epidemics. And it demonstrates impact with clear performance indicators.

A "business case" for the Global Fund is clear. Its impact is profound, and reasons to support it are many.

Return on investment: Since its 2002 launch, the Global Fund and its partners have saved more than 59 million lives, reducing the combined death toll from HIV/AIDS, TB, and malaria by 55% in countries in where it invests. In 2022 alone, the Global Fund partnership provided antiretroviral treatment for 24.5

million people with HIV, treated 6.7 million people for TB, and funded the distribution of over 220 million bed nets for malaria prevention. In critical diagnostics, it made possible 12.2 million HIV tests for priority and key populations, and 321 million malaria tests for suspected cases. It is estimated that a \$1.2 billion contribution in FY25 would save 1.4 million lives, avert 30 million new infections and secure \$35 billion in economic returns.

Strengths and capabilities: The Global Fund’s operational effectiveness, agility, inclusivity, and unique partnership model set it apart among global health initiatives. The Global Fund’s operating expenditure as a percentage of donor contributions has steadily decreased, and is 5.1%, significantly below most comparable organizations. Working with over 120 countries, the Global Fund maintains accountability through exacting impact metrics, an independent Inspector General, and whistleblower protection.

The Global Fund strengthens health systems. Through large-scale pooled procurement and robust supply chains, it increases affordability and availability of health commodities, while incentivizing and spreading innovation. It invests in local health workers to combat HIV/AIDS, TB, and malaria, while also enhancing preparedness for future pandemic threats. Global Fund collaboration with U.S. bilateral global health programs is mutually reinforcing and crucial for the success of both.

Return on investment to Americans: Investing in programs like the Global Fund enhances worldwide health infrastructure, economies, and stability while bolstering Americans’ health security by curbing disease spread globally. It benefits the U.S. economy through healthier citizens and workforces. Every dollar invested in the Global Fund yields \$31 in economic benefits. The match requirement has rallied other nations’ burden-sharing, leveraging taxpayers’ money for more impact.

Tackling colliding crises: The goal of ending the AIDS, TB, and malaria epidemics faces several obstacles, despite much progress. An accelerating erosion of political and civil freedoms globally means that marginalized populations bear a disproportionate burden of disease. Conflict, extreme weather events and involuntary displacement put vulnerable populations more at risk from the deadliest infectious diseases. Multidrug resistance and resistance to malaria bed net insecticides are rising at a disturbing rate. No organization is better positioned to overcome these challenges than the Global Fund.

The Global Fund is a proven investment offering unparalleled returns for health, prosperity and security. Thank you for your stewardship and vision in continuing strong support for this lifesaving initiative.

Sincerely,

Abbott	(RED)
BD	Roche
Cepheid	SC Johnson & Son, Inc.
Dimagi	Sanaria
Johnson & Johnson	The Coca-Cola Company
Kainomyx, Inc.	Thermo Fisher Scientific
Medtronic LABS	Vestergaard
Merck	Viatrix
MTV Staying Alive Foundation	ViiV Healthcare
Pendulum	Zenysis